Gitnux/Report 2026

Compounding Pharmacy Industry Statistics

The global compounding pharmacies market is estimated at $18.9 billion in 2026, explore the figures behind growth, companies and trends.
23Statistics
29Sources
4Sections
1Visuals
16mRead
Compounding Pharmacy Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days

01 Industry overview

The compounding pharmacy industry at a glance

The global compounding pharmacies market is estimated at $18.9 billion in 2026 and is forecast to reach $31.4 billion by 2033, supported by personalized medicines, drug shortages and demand for alternative dosage forms.

$18.9B[1]
Global market size, 2026
7.5%[1]
Global CAGR, 2026–2033
97[5]
U.S. 503B facilities, FY2025
43.0%[1]
North America share, 2025
Market size
The global compounding pharmacies market was valued at $17.6 billion in 2025 and is estimated at $18.9 billion in 2026. The U.S. market was estimated at $6.3 billion in 2025 by one market study, although published estimates vary because market definitions differ.[1][13]
Forecast & CAGR
The global market is forecast to grow from $18.9 billion in 2026 to $31.4 billion in 2033, representing a 7.5% CAGR. A separate forecast estimates the U.S. market will increase from $6.3 billion in 2025 to $10.8 billion in 2034 at a 6.2% CAGR.[1][13]
Market share & regions
North America held the largest regional share at 43.0% of global revenue in 2025. Another market estimate places North America’s share at 37.44%, illustrating the effect of differing market scopes and methodologies.[1][4]
Segmentation
In 2025, pain management accounted for more than 33.0% of global revenue, adults represented more than 44.0%, pharmaceutical ingredient alteration exceeded 37.0%, and sterile products accounted for more than 58.0%. These segments are commonly analyzed by therapeutic area, age cohort, compounding type and sterility.[1]
Key players & concentration
The U.S. market includes many 503A patient-specific pharmacies and a smaller 503B outsourcing-facility segment. FDA counted 97 registered outsourcing facilities geographically during FY2025, including 31 in the Southeast, 21 in the Southwest, 20 in the Northeast, 14 in the West and 11 in the Midwest; the available data do not establish a national revenue concentration ratio.[5]
Trends, drivers & challenges
Demand is being supported by personalized dosing, dosage-form changes, allergies, medication shortages and the need to compound products unavailable from commercial manufacturers. The main challenges are sterile-production quality, regulatory compliance, variable reimbursement and the safety risks associated with compounded products; FDA reported that 93 facilities remained registered through the end of FY2025, compared with 83 in FY2024.[1][5]
Consumer behavior & competition
Compounding pharmacies compete by offering customized strengths, flavors, delivery forms and allergen-free formulations when an FDA-approved product is not medically appropriate. Market research identifies medication-adherence barriers such as swallowing difficulty, taste preferences and allergies as demand drivers, while the industry remains fragmented between local 503A pharmacies, national specialty operators and 503B suppliers.[5][1]
M&A
M&A activity continued in 2025 and 2026. Fagron agreed to acquire University Compounding Pharmacy in September 2025 for approximately $41.5 million, while The Wellness Group announced an agreement in October 2026 to acquire Skip’s Pharmacy, its second pharmacy acquisition in 12 months.[9][14]
Regulation
U.S. federal rules distinguish traditional state-licensed compounding under section 503A from FDA-registered outsourcing facilities under section 503B. Updated USP Chapters <795> and <797> became effective November 1, 2023, while California’s revised compounding regulations took effect October 1, 2025 and incorporate USP <795>, <797>, <800> and <825>.[5][15][16]
Latest news
As of November 17, 2026, FDA’s public register listed 503B outsourcing facilities with registrations current through the latest weekly data lock. Recent industry developments include FDA’s continuing oversight of compounded drugs, the 2026 sale of Central Admixture Pharmacy Services’ 503B product portfolio to Quva Pharma, and The Wellness Group’s announced acquisition of Skip’s Pharmacy.[5][17][14]

02 Ranking

Top 10 Companies in the Compounding Pharmacy Industry

The leading companies in the compounding pharmacy industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 21, 2026 · Next review December 21, 2026

Verdict

Fagron leads the compounding pharmacy industry with an 15.4% operating margin tied to its 9.2% revenue growth, while Empower Pharmacy stands out as a state-licensed pharmacy with the largest 503A compounding pharmacy and 503B outsourcing facility in the country.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in global compounding products

    Fagron

    BE

    Ranked #1 · 9.1 · Global compounding products

    Why we picked it: It sells pharmaceutical compounding products and services globally, with an 15.4% operating margin.

  2. Leader in 503A compounding pharmacy

    Empower Pharmacy

    US

    Ranked #2 · 9.0 · 503A compounding pharmacy

    Why we picked it: It focuses on human 503A compounding and 503B outsourcing in the United States.

  3. Leader in 503B sterile compounding

    Olympia Pharmacy

    US

    Ranked #3 · 9.0 · 503B sterile compounding

    Why we picked it: It runs both a 503B outsourcing facility and a 503A pharmacy, spanning 49 states.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the compounding pharmacy industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Fagron

Global compounding products · BE

9.1
2

Empower Pharmacy

503A compounding pharmacy · US

9.0
3

Olympia Pharmacy

503B sterile compounding · US

9.0
4

Leiters Health

503B sterile compounding · US

8.9
5

Medisca

Compounding supply · CA

8.8
6

Revelation Pharma

503A and 503B pharmacy network, United States · US

8.6
7

Harrow

Ophthalmic compounding through ImprimisRx · US

8.6
8

PCCA

Compounding ingredients, education and support · US

8.4
9

B. Braun

Hospital sterile compounding through CAPS · DE

7.9
10

McGuff

503A and 503B sterile compounding, United States · US

7.4

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 21, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 21). Top 10 companies in the compounding pharmacy industry. In Compounding Pharmacy Industry Statistics. Gitnux. https://gitnux.org/compounding-pharmacy-industry-statistics/#top-companies

report visual · Projection

U.S. compounding pharmacies market size

U.S. compounding pharmacies market size grew from $5.2B in 2021 to $6.0B in 2024.

$5.2B
Start
+4.89%
CAGR · 3y
$6B
Projected
20212024
source-verifiedgminsights.com2024

04 Statistics

Market Intelligence

This section anchors demand with global and U.S. revenue estimates, plus the registered outsourcing-facility counts used to interpret 503B capacity.

Market size and service revenue in the compounding pharmacy industry

  • USD 5,131.1 million was U.S. compounding pharmacies market revenue in 2023; the study covers compounded-pharmacy services segmented by therapeutic area, including hormone replacement, pain management, dermatology and nutritional supplements.[1]
  • USD 12.98 billion was the global compounding pharmacy market value in 2024; the study defines the category as pharmacists creating tailored medications by therapeutic area, route of administration, end user and region.[2]
  • USD 17.6 billion was the global compounding pharmacies market value in 2025; the study defines the category as pharmacies creating personalized medications, segmented by therapeutic area, age cohort, compounding type and sterility.[1]
  • USD 4,743.43 million was the U.S. compounding pharmacies market value in 2024; the publisher covers pharmacy compounding services and reports the market by competitors, geography and product or service segments.[3]

Growth forecasts for the compounding pharmacy industry

  • A 6.52% CAGR is projected for the global compounding pharmacy market from 2025 to 2030, reaching USD 18.96 billion in 2030; the study covers tailored medications by therapeutic area, route, end user and region.[2]
  • A 7.5% CAGR is projected for the global compounding pharmacies market from 2026 to 2033, reaching USD 31.4 billion in 2033; the study covers personalized compounding pharmacy services by therapeutic area, age cohort, compounding type and sterility.[1]
  • A 5.68% CAGR is projected for the global compounding pharmacy market from 2026 to 2031, rising from USD 15.83 billion in 2025 to USD 22.08 billion in 2031; the publisher covers compounding pharmacy services by geography and segment.[4]

Firm counts and size structure in the compounding pharmacy industry

  • 93 U.S. outsourcing facilities remained registered at the end of FDA fiscal year 2025.[5]
  • 97 entities registered as U.S. human-drug compounding outsourcing facilities during FDA fiscal year 2025.[5]
  • 4 U.S. outsourcing facilities registered and then de-registered during FDA fiscal year 2025.[5]

Regional breakdown of the compounding pharmacy industry

  • The United States represented 39.1% of global compounding pharmacies market revenue in 2023; the publisher defines the category as compounding pharmacy services measured in revenue by therapeutic area.[1]
  • North America accounted for 43.0% of global compounding pharmacies market revenue in 2025; the publisher defines the category as compounding pharmacy services segmented by therapeutic area, age cohort, compounding type and sterility.[1]
  • Asia Pacific compounding pharmacies market value was estimated at USD 1.67 billion in 2025; the publisher covers regional compounding pharmacy services and reports regional value, share and growth.[6]

05 Statistics

Strategy & Growth

This section lists deal flow snapshots, including a reported $41.5 million acquisition tied to Fagron’s U.S. compounding-pharmacy platform.

M&A and consolidation in the compounding pharmacy industry

  • 24 specialty-pharmacy transactions were announced in the United States in 2024; specialty pharmacy is the parent category used because no comprehensive compounding-pharmacy transaction series was identified.[7]
  • C$22.5 million was the reported acquisition price for The Compounding Pharmacy of Manitoba by Grey Wolf Animal Health on December 2, 2024.[8]
  • $41.5 million was the reported acquisition price for University Compounding Pharmacy by Fagron in September 2025, expanding Fagron’s U.S. compounding-pharmacy platform.[9]

06 Statistics

People & Workforce

This section quantifies accreditation and certification validity periods used for provisioning workforce compliance in compounding operations.

Skills and certification in the compounding pharmacy industry

  • 3 years is the validity period for NABP Compounding Pharmacy Accreditation under the program’s current accreditation standards for U.S. compounding pharmacies; the program page states the requirement is in force.[10]
  • June 1, 2024 was the effective date for ACHC PCAB revised CFNS standards incorporating USP Chapter <795> updates for compounding-pharmacy accreditation in the United States.[11]
  • 2 years is the validity period for Joint Commission Medication Compounding Certification under the current certification program for eligible U.S. organizations providing sterile or nonsterile compounding.[12]

07 Statistics

Risk & Compliance

This section provides oversight intensity and outcomes, including FDA re-inspections and total inspections of U.S. outsourcing facilities in fiscal year 2025.

Regulation and licensing in the compounding pharmacy industry

  • 17 FDA re-inspections of U.S. outsourcing facilities were conducted in fiscal year 2025 under the Compounding Quality Act.[5]
  • 42 FDA inspections of U.S. outsourcing facilities were conducted in fiscal year 2025, including surveillance, follow-up and for-cause inspections.[5]
  • 93 U.S. outsourcing facilities remained registered with FDA at the end of fiscal year 2025 under section 503B of the FD&C Act.[5]
  • $2,219,440 in outsourcing-facility fees was collected by FDA in fiscal year 2025 to support oversight of registered compounding outsourcing facilities.[5]

Key questions about the compounding pharmacy industry

What is the global market size for compounding pharmacies in 2026?
The global compounding pharmacies market is estimated at $18.9 billion in 2026.
How fast is the market expected to grow from 2026 to 2033?
The global market is forecast to grow from $18.9 billion in 2026 to $31.4 billion in 2033, a 7.5% CAGR.
Which companies lead the compounding pharmacy industry?
Fagron leads the compounding pharmacy industry with an 15.4% operating margin tied to its 9.2% revenue growth, while Empower Pharmacy stands out as a state-licensed pharmacy with the largest 503A compounding pharmacy and 503B outsourcing facility in the country.
What technology or standards shifts are shaping compounding operations?
Updated USP Chapters <795> and <797> became effective November 1, 2023, and California’s revised compounding regulations took effect October 1, 2025 and incorporate USP <795>, <797>, <800> and <825>.
How is the U.S. outsourcing-facility base changing under FDA oversight?
FDA reported 97 entities registered as U.S. human-drug compounding outsourcing facilities during fiscal year 2025, and 93 facilities remained registered at the end of fiscal year 2025 under section 503B.
What concentration of facilities does the FDA register show by geography in FY2025?
FDA counted 97 registered outsourcing facilities geographically during FY2025: 31 in the Southeast, 21 in the Southwest, 20 in the Northeast, 14 in the West, and 11 in the Midwest.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 21). Compounding Pharmacy Industry Statistics. Gitnux. https://gitnux.org/compounding-pharmacy-industry-statistics
MLA
Samuel Norberg. "Compounding Pharmacy Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/compounding-pharmacy-industry-statistics.
Chicago
Samuel Norberg. 2026. "Compounding Pharmacy Industry Statistics." Gitnux. https://gitnux.org/compounding-pharmacy-industry-statistics.